Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.63 +0.1%	$4.64	$2.90 ▼ $11.16	$319.93M	-0.01	3.77 million shs	1.97 million shs
IMAB I-Mab	$4.54 +7.7%	$2.68	$0.60 ▼ $5.90	$370.41M	1.38	924,703 shs	1.44 million shs
MGX Metagenomi	$1.84 +0.6%	$1.90	$1.23 ▼ $4.92	$69.10M	-0.12	687,191 shs	129,665 shs
MRNA Moderna	$26.88 -3.7%	$29.21	$23.15 ▼ $88.59	$10.46B	1.83	10.70 million shs	5.66 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+1.69%	0.00%	-11.27%	-35.24%	-51.99%
IMAB I-Mab	-17.29%	+9.35%	+100.48%	+346.35%	+253.78%
MGX Metagenomi	-4.69%	-2.66%	-8.04%	+10.91%	-41.90%
MRNA Moderna	-0.64%	+8.77%	-10.72%	+8.18%	-68.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	3.1956 of 5 stars	4.3	3.0	0.0	1.8	1.7	0.6
IMAB I-Mab	3.3212 of 5 stars	3.7	5.0	0.0	3.3	1.7	0.0
MGX Metagenomi	2.4237 of 5 stars	3.5	2.0	0.0	2.2	1.7	0.6
MRNA Moderna	4.386 of 5 stars	4.0	2.0	4.6	1.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.57	Moderate Buy	$17.40	385.36% Upside
IMAB I-Mab	3.33	Buy	$6.00	33.19% Upside
MGX Metagenomi	3.00	Buy	$10.00	443.48% Upside
MRNA Moderna	2.04	Hold	$43.59	62.86% Upside

Current Analyst Ratings Breakdown

Latest MGX, MRNA, ALT, and IMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	MGX Metagenomi	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
8/15/2025	MGX Metagenomi	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
8/14/2025	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $12.00
8/13/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
8/13/2025	ALT Altimmune	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $24.00
8/13/2025	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
8/4/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$40.00 ➝ $31.00
8/1/2025	MRNA Moderna	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$32.00
8/1/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$26.00
8/1/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
8/1/2025	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight	$32.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$20K	15,820.07	N/A	N/A	$1.83 per share	1.96
IMAB I-Mab	N/A	N/A	N/A	N/A	$2.47 per share	N/A
MGX Metagenomi	$33.77M	2.05	N/A	N/A	$5.22 per share	0.35
MRNA Moderna	$3.06B	3.41	N/A	N/A	$24.16 per share	1.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$95.06M	-$1.18	N/A	N/A	N/A	-438,730.03%	-62.63%	-55.29%	N/A
IMAB I-Mab	-$22.23M	N/A	0.00	N/A	N/A	N/A	-19.81%	-18.63%	8/20/2025 (Estimated)
MGX Metagenomi	-$78.06M	-$2.36	N/A	N/A	N/A	-257.99%	-37.84%	-27.15%	N/A
MRNA Moderna	-$3.56B	-$7.53	N/A	N/A	N/A	-94.31%	-25.96%	-20.09%	11/6/2025 (Estimated)

Latest MGX, MRNA, ALT, and IMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2025	Q2 2025	IMAB I-Mab	-$0.10	-$0.07	+$0.03	-$0.07	N/A	N/A
8/12/2025	Q2 2025	ALT Altimmune	-$0.32	-$0.27	+$0.05	-$0.27	$0.00 million	$0.01 million
8/12/2025	Q2 2025	MGX Metagenomi	-$0.68	-$0.54	+$0.14	-$0.54	$7.72 million	$8.51 million
8/1/2025	Q2 2025	MRNA Moderna	-$2.99	-$2.13	+$0.86	-$2.13	$116.26 million	$142.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	0.09	20.44	20.44
IMAB I-Mab	N/A	22.35	22.35
MGX Metagenomi	N/A	6.36	6.36
MRNA Moderna	N/A	3.93	3.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
IMAB I-Mab	38.38%
MGX Metagenomi	N/A
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
IMAB I-Mab	22.10%
MGX Metagenomi	17.80%
MRNA Moderna	11.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	88.26 million	84.64 million	Optionable
IMAB I-Mab	380	81.66 million	63.61 million	Optionable
MGX Metagenomi	236	37.53 million	30.85 million	N/A
MRNA Moderna	5,800	389.08 million	346.28 million	Optionable

MGX, MRNA, ALT, and IMAB Headlines

Recent News About These Companies

Federal funding cuts impact mRNA vaccine developments in S.C.

1 hour ago | msn.com

28,886 Shares in Moderna, Inc. $MRNA Acquired by Freestone Capital Holdings LLC

August 20 at 6:48 AM | marketbeat.com

Funding cuts to impact mRNA vaccine development efforts in SC

August 20 at 2:28 AM | msn.com

Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Recommendation of "Hold" from Brokerages

August 20 at 2:55 AM | americanbankingnews.com

National Pension Service Decreases Stock Holdings in Moderna, Inc. $MRNA

August 19 at 4:55 AM | marketbeat.com

mRNA vaccine funding cuts: the impact on U.S. healthcare and biotech

August 18 at 12:48 PM | labiotech.euL

Illinois researchers fear mRNA vaccine cuts will set back cancer, rare disease work

August 18 at 12:48 PM | chicagobusiness.comC

Kennedy’s mRNA cuts could set US science back, experts warn

August 18 at 12:48 PM | biopharmadive.comB

Moderna (NASDAQ:MRNA) Stock Price Up 6.6% - Time to Buy?

August 17 at 3:00 PM | marketbeat.com

If You're in Your 30s, Consider Buying These 2 Healthcare Stocks

August 17 at 9:30 AM | fool.com

Neuberger Berman Group LLC Grows Stock Position in Moderna, Inc. (NASDAQ:MRNA)

August 17 at 5:32 AM | marketbeat.com

Traders Buy High Volume of Moderna Call Options (NASDAQ:MRNA)

August 17 at 2:19 AM | marketbeat.com

Invesco Ltd. Grows Holdings in Moderna, Inc. (NASDAQ:MRNA)

August 16, 2025 | marketbeat.com

UK Court of Appeal Upholds Moderna mRNA Patent Against Pfizer/BioNTech

August 16, 2025 | jdsupra.com

RFK Jr.’s mRNA hostility could hurt more than just vaccines

August 15, 2025 | bostonglobe.comB

Scientists: mRNA Vaccine Research Cuts Undermine U.S. Innovation

August 15, 2025 | insidehighered.comI

RFK risks us all in targeting mRNA vaccine research

August 15, 2025 | grandhaventribune.comG

Moderna, Inc. (NASDAQ:MRNA) Stake Raised by Charles Schwab Investment Management Inc.

August 15, 2025 | marketbeat.com

RFK Jr. Creates More Vaccine Misinformation With mRNA Cancellations

August 14, 2025 | biospace.comB

Blair William & Co. IL Has $289,000 Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

August 14, 2025 | marketbeat.com

Saving lives no more: RFK risks us all in targeting mRNA vaccine research

August 13, 2025 | nydailynews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MGX, MRNA, ALT, and IMAB Company Descriptions

Altimmune NASDAQ:ALT

$3.62 +0.01 (+0.14%)

Closing price 03:59 PM Eastern

Extended Trading

$3.62 -0.01 (-0.28%)

As of 04:14 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

I-Mab NASDAQ:IMAB

$4.54 +0.33 (+7.74%)

Closing price 03:59 PM Eastern

Extended Trading

$4.40 -0.14 (-2.98%)

As of 04:11 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Metagenomi NASDAQ:MGX

$1.84 +0.01 (+0.60%)

Closing price 03:59 PM Eastern

Extended Trading

$1.87 +0.03 (+1.79%)

As of 04:15 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Moderna NASDAQ:MRNA

$26.88 -1.03 (-3.69%)

Closing price 03:59 PM Eastern

Extended Trading

$26.88 -0.01 (-0.02%)

As of 04:15 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time